Acelyrin

ACELYRIN INC

Acelyrin Inc is a late-stage clinical biopharmaceutical company. The clinical biopharma segment researches and develops treatments for diseases with pathology related to excess activation of the immune system. It is focused on providing patients with life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines.

Konskie,,Poland,-,December,03,,2024:,Rpm,International,Company,Logo

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

AMST

CTAS

GETY

HOTH

LFWD

SLRN

SSTK

Nasdaq Down 1.5%; RPM Posts Upbeat Results

Wall Street

LIDR

XTIA

Dow Surges Over 100 Points; US Trade Deficit Widens In November

Price Action

Pre-Market Outlook

Movers

COGT

NPCE

THRD

TKNO

TSLA

YMAB

Acelyrin, Tesla And Other Big Stocks Moving Lower In Tuesday&#39;s Pre-Market Session

Acelyrin Inc

Legal

Press Releases

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IPG, SLRN, PTMN, HEES on Behalf of Shareholders

Health Care

ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences

Kuehn Law Encourages NVRO, SLRN, TGI, and PTMN Investors to Contact Law Firm

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NVRO, TGI, PTMN, SLRN on Behalf of Shareholders

ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger

ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger

ACELYRIN Adopts Limited-Duration Stockholder Rights Plan

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RDW, BHLB, MHLD, SLRN on Behalf of Shareholders

STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating The Merger - SLRN, TURN, BHLB, MHLD

Comments

Acelyrin

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga